As for BRAFV600E-negative cases that overexpress MDM2, it should be noticed that MAPK-activating mutations other than BRAFV600E have been identified in ameloblastomas [16], and in some ameloblastomas the TGF-β pathway may be activated [71]. The gene discussed is MDM2; the disease is ameloblastoma.